Pallas Health vs CoreAgeRx: Brand or Flat Monthly Pricing
Quick verdict: Pallas Health emphasizes clinician choice between FDA-approved brand-name GLP-1s and compounded options with a first-month compounded semaglutide price of $139 (then $199/mo average), while CoreAgeRx positions flat monthly pricing with tirzepatide at $129/mo and semaglutide at $79/mo. If you want clinician-selected brand versus compounded options, Pallas leans toward that; if you want predictable flat monthly billing, CoreAgeRx emphasizes price stability.
See Pallas Health plans starting at $139
How they differ: medication options and pricing structure
Pallas Health vs CoreAgeRx contrast mainly on what medications are offered and how you pay. Pallas presents both FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. CoreAgeRx highlights fixed monthly pricing and lists tirzepatide at $129 per month and semaglutide at $79 per month up to specified doses.
Medication selection and regulatory notes
Pallas explicitly offers brand-name GLP-1s and compounded alternatives; its description includes that compounded medications are prepared by US-licensed compounding pharmacies and that compounded medications are not FDA-approved. CoreAgeRx notes medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both rely on a licensed clinician to determine appropriateness.
Pricing mechanics and transparency
Pallas charges compounded semaglutide $139 for the first month, then $597 every 12 weeks (a $199/month average), and compounded tirzepatide $179 first month then $897 every 12 weeks ($299/mo average). Pallas also lists cash-pay brand prices for Wegovy, Zepbound, Ozempic and Mounjaro. CoreAgeRx emphasizes same price every month with no membership fee and advertises tirzepatide $129/mo and semaglutide $79/mo and states no price hike as dose increases up to advertised limits.
Three distinctive differences to weigh
1. Brand-name availability versus flat monthly pricing
Pallas explicitly offers clinician choice between brand-name pens and compounded products as part of one intake. CoreAgeRx emphasizes flat monthly pricing across treatment, with specific monthly rates for tirzepatide and semaglutide and messaging that prices do not increase in later months.
2. Compounded renewal cadence and plan pricing
Pallas compounds its plans and renews compounded semaglutide every 12 weeks at $597 rather than billing strictly monthly, which yields a $199/month average. CoreAgeRx conveys a same-price-every-month model and stresses no sudden bill doubling later in treatment.
3. Visit format and clinician review
Pallas is 100 percent online and asynchronous in most states, noting that a video visit is required in seven states plus Washington, D.C. CoreAgeRx advertises a 3-minute online visit and says treatment is available only when a licensed clinician determines it is medically appropriate; captured landing-page evidence did not publish all state or visit exceptions.
Comparison table
| Criterion | Pallas Health | CoreAgeRx |
|---|---|---|
| Primary positioning | Clinician chooses brand-name or compounded GLP-1 | Same price every month; flat monthly pricing |
| Compounded semaglutide price | First month $139, then $597 every 12 weeks ($199/mo avg) | Not published for compounded product; semaglutide listed $79/mo |
| Tirzepatide price | Compounded tirzepatide $179 first month, then $897 every 12 weeks ($299/mo avg) | Advertised $129 per month up to 7.5 mg |
| Brand-name availability | Offers Wegovy, Ozempic, Zepbound and Mounjaro as cash-pay options | Medication-specific approval status must be confirmed; branded vs compounded not interchangeable |
| Visit format and states | 100% online; asynchronous in most states, video visit required in seven states plus D.C. | 3-minute online visit; state coverage and eligibility cautioned |
| Shipping and fees | Free expedited discreet shipping; cash-pay only; no membership fee | No membership fee; landing-page details on shipping not fully published |
View CoreAgeRx flat monthly pricing
Care, eligibility and limitations
Both providers require clinician review to determine eligibility and appropriate medication. Pallas states eligibility is determined by a US-licensed clinician and that it does not manufacture or compound medication. CoreAgeRx warns that pricing, eligibility, pharmacy, state coverage and renewal terms may change and that treatment is available only when a licensed clinician determines it is medically appropriate. Both note that compounded medications are not FDA-approved where relevant.
Compare Pallas clinician options and brand prices
Final thoughts on Pallas Health vs CoreAgeRx
In short, Pallas Health centers on clinician-led selection between FDA-approved brand-name GLP-1s and compounded preparations with introductory compounded pricing such as $139 first month for semaglutide and renewal cadence every 12 weeks. CoreAgeRx centers on predictable flat monthly pricing with listed rates like tirzepatide $129/mo and semaglutide $79/mo and messaging that price does not rise later in treatment. Which matters most will depend on whether you prioritize clinician choice of brand versus compounded products or predictable month-to-month cost stability.
Check CoreAgeRx pricing and enrollment
Choose Pallas Health if you want a clinician to pick between a brand-name GLP-1 pen and a per-patient compounded preparation and you value a single intake that includes both routes. Choose CoreAgeRx if predictable flat monthly pricing for semaglutide or tirzepatide and explicit same-price-every-month messaging is the priority.